Review of the Multicenter Trial Committee report : a prospective , randomized study on the <font color="blue">prophylaxis_1</font> <font color="blue">of_1</font> <font color="blue">postoperative_2</font> <font color="blue">deep_2</font> <font color="blue">venous_2</font> <font color="blue">thrombosis_2</font> <font color="blue">._2</font> 
<br>
<br> The etiology of <font color="blue">postoperative_1</font> <font color="blue">deep_2</font> <font color="blue">venous_2</font> <font color="blue">thrombosis_2</font> <font color="blue">(_1</font> <font color="blue">DVT_1</font> <font color="blue">)_1</font> is thought to be due to a combination of factors including <font color="blue">stasis_1</font> <font color="blue">,_1</font> <font color="blue">a_1</font> <font color="blue">hypercoagulable_1</font> <font color="blue">state_1</font> <font color="blue">and_1</font> <font color="blue">venous_1</font> <font color="blue">endothelial_1</font> <font color="blue">damage_1</font> <font color="blue">._1</font> Methods of prophylaxis are directed toward correcting one or more of these pathologic events . Methods counteracting more than one of these factors can be expected to be even more effective . The combination of dihydroergotamine ( DHE ) and heparin was anticipated to minimize stasis and the hypercoagulable state respectively . Based upon current experimental evidence and current theory , an additional benefit might include minimizing venous endothelial injury by controlling venomotor tone . A prospective , randomized , double - blind , multicenter trial was designed and performed in the <font color="blue">United_2</font> <font color="blue">States_2</font> evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U , DHE 0.5 mg plus heparin 2500 U , heparin 5000 U , and DHE 0.5 mg versus placebo . <font color="blue">General_4</font> <font color="blue">surgical_4</font> <font color="blue">patients_4</font> <font color="blue">including_4</font> <font color="blue">those_4</font> <font color="blue">undergoing_4</font> <font color="blue">noncardiac_4</font> <font color="blue">thoracic_4</font> <font color="blue">and_4</font> <font color="blue">pelvic_4</font> <font color="blue">operations_4</font> <font color="blue">who_4</font> <font color="blue">were_4</font> <font color="blue">identified_4</font> <font color="blue">at_4</font> <font color="blue">moderate_4</font> <font color="blue">to_4</font> <font color="blue">high_4</font> <font color="blue">risk_4</font> <font color="blue">for_4</font> <font color="blue">postop_4</font> <font color="blue">DVT_4</font> <font color="blue">were_2</font> <font color="blue">included_2</font> <font color="blue">._2</font> Study medications were injected subcutaneously two hours preoperatively and every 12 hours postoperatively for 5 - 7 days or until the 125I - fibrinogen - uptake test ( RFUT ) became positive . <font color="blue">Eight_3</font> <font color="blue">hundred_3</font> <font color="blue">and_3</font> <font color="blue">eighty_3</font> <font color="blue">eight_3</font> <font color="blue">patients_3</font> <font color="blue">were_1</font> <font color="blue">entered_1</font> <font color="blue">into_1</font> <font color="blue">this_1</font> <font color="blue">trial_1</font> <font color="blue">and_1</font> <font color="blue">744_2</font> <font color="blue">(_1</font> <font color="blue">85%_1</font> <font color="blue">)_1</font> <font color="blue">completed_1</font> <font color="blue">the_1</font> <font color="blue">study_1</font> <font color="blue">._1</font> Results showed a statistically significant benefit from DHE / Hep 5000 compared to placebo ( p less than 0.01 ) and compared to other active agents ( p less than 0.05 ) . None of the other active agents showed a statistically significant prophylactic benefit.(ABSTRACT TRUNCATED AT 250 WORDS )